Comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological DMARDS

Objective: Rheumatoid arthritis (RA) is an inflammatory, autoimmune systemic disease. This study aimed to compare the demographic, clinical characteristics, treatment choices, and treatment responses of seronegative (SN) and seropositive (SP) RA patients who were receiving or newly started biologica...

Full description

Saved in:
Bibliographic Details
Main Authors: Zehra Özsoy, Şerife Asya Germe, Gizem Ayan, Güllü Sandal Uzun, Mustafa Ekici, Erdinç Ünaldı, Levent Kılıç, Ali Akdoğan, Şule Apras Bilgen, Sedat Kiraz, Ali İhsan Ertenli
Format: Article
Language:English
Published: Turkish Society for Rheumatology 2025-03-01
Series:Ulusal Romatoloji Dergisi
Subjects:
Online Access:https://www.raeddergisi.org/articles/comparison-of-seropositive-and-seronegative-rheumatoid-arthritis-patients-using-or-about-to-be-initiated-with-biological-dmards/doi/raed.galenos.2025.22043
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850095688624373760
author Zehra Özsoy
Şerife Asya Germe
Gizem Ayan
Güllü Sandal Uzun
Mustafa Ekici
Erdinç Ünaldı
Levent Kılıç
Ali Akdoğan
Şule Apras Bilgen
Sedat Kiraz
Ali İhsan Ertenli
author_facet Zehra Özsoy
Şerife Asya Germe
Gizem Ayan
Güllü Sandal Uzun
Mustafa Ekici
Erdinç Ünaldı
Levent Kılıç
Ali Akdoğan
Şule Apras Bilgen
Sedat Kiraz
Ali İhsan Ertenli
author_sort Zehra Özsoy
collection DOAJ
description Objective: Rheumatoid arthritis (RA) is an inflammatory, autoimmune systemic disease. This study aimed to compare the demographic, clinical characteristics, treatment choices, and treatment responses of seronegative (SN) and seropositive (SP) RA patients who were receiving or newly started biological treatment. Methods: The files and records of patients registered with Hacettepe University Biological Database with RA diagnosis who were planned to use biological disease-modifying antirheumatic drugs (b-DMARDs) between 2010-2024 were scanned. RA patients were divided into two groups as SPRA and SNRA. Demographic characteristics, disease duration, bDMARD use follow-up period, comorbidities, RA extra-articular findings, visual analog scale (VAS) global, VAS pain, VAS fatigue, Health Assessment Questionnaire-Disability index were recorded for RA patients included in the study. Results: Two thousand five hundred and fifty-nine patients were included in the study. Median age of the patients was 55 years and 2034 of them were female. 75% of the patients were SPRA, 25% were SNRA. Although the DAS-28 score did not create a statistically significant difference when compared between the two groups, the rate of patients with low disease activity was higher in the seronegative group, while the rate of patients with moderate and high disease activity was higher in the SPRA group. When patients were evaluated according to the disease activity score (DAS-28) disease activity score after b-DMARD treatment, the proportion of patients who achieved remission or low disease activity was higher in the seronegative group. Among extra-articular findings, the frequency of interstitial lung disease and sicca symptoms were higher in the SPRA group. Conclusion: SPRA and SNRA can be considered as two separate subtypes of RA with differences in clinical features, extra-articular involvement findings, disease activities, treatment choices and treatment responses.
format Article
id doaj-art-d229d9593abe4645882ab655a763dccd
institution DOAJ
issn 2651-2653
2651-2661
language English
publishDate 2025-03-01
publisher Turkish Society for Rheumatology
record_format Article
series Ulusal Romatoloji Dergisi
spelling doaj-art-d229d9593abe4645882ab655a763dccd2025-08-20T02:41:23ZengTurkish Society for RheumatologyUlusal Romatoloji Dergisi2651-26532651-26612025-03-01171535910.4274/raed.galenos.2025.22043Comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological DMARDSZehra Özsoy0https://orcid.org/0000-0002-4534-4929Şerife Asya Germe1https://orcid.org/0009-0001-4068-9899Gizem Ayan2https://orcid.org/0000-0003-1889-9619Güllü Sandal Uzun3https://orcid.org/0000-0002-5010-9114Mustafa Ekici4https://orcid.org/0000-0002-8757-6226Erdinç Ünaldı5https://orcid.org/0009-0005-4381-202XLevent Kılıç6https://orcid.org/0000-0003-1064-9690Ali Akdoğan7https://orcid.org/0000-0001-6895-9144Şule Apras Bilgen8https://orcid.org/0000-0001-8208-1585Sedat Kiraz9https://orcid.org/0000-0003-2802-6061Ali İhsan Ertenli10https://orcid.org/0000-0002-3904-0769Hacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeHacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, TürkiyeObjective: Rheumatoid arthritis (RA) is an inflammatory, autoimmune systemic disease. This study aimed to compare the demographic, clinical characteristics, treatment choices, and treatment responses of seronegative (SN) and seropositive (SP) RA patients who were receiving or newly started biological treatment. Methods: The files and records of patients registered with Hacettepe University Biological Database with RA diagnosis who were planned to use biological disease-modifying antirheumatic drugs (b-DMARDs) between 2010-2024 were scanned. RA patients were divided into two groups as SPRA and SNRA. Demographic characteristics, disease duration, bDMARD use follow-up period, comorbidities, RA extra-articular findings, visual analog scale (VAS) global, VAS pain, VAS fatigue, Health Assessment Questionnaire-Disability index were recorded for RA patients included in the study. Results: Two thousand five hundred and fifty-nine patients were included in the study. Median age of the patients was 55 years and 2034 of them were female. 75% of the patients were SPRA, 25% were SNRA. Although the DAS-28 score did not create a statistically significant difference when compared between the two groups, the rate of patients with low disease activity was higher in the seronegative group, while the rate of patients with moderate and high disease activity was higher in the SPRA group. When patients were evaluated according to the disease activity score (DAS-28) disease activity score after b-DMARD treatment, the proportion of patients who achieved remission or low disease activity was higher in the seronegative group. Among extra-articular findings, the frequency of interstitial lung disease and sicca symptoms were higher in the SPRA group. Conclusion: SPRA and SNRA can be considered as two separate subtypes of RA with differences in clinical features, extra-articular involvement findings, disease activities, treatment choices and treatment responses.https://www.raeddergisi.org/articles/comparison-of-seropositive-and-seronegative-rheumatoid-arthritis-patients-using-or-about-to-be-initiated-with-biological-dmards/doi/raed.galenos.2025.22043rheumatoid arthritisseropositiveseronegativeb-dmard
spellingShingle Zehra Özsoy
Şerife Asya Germe
Gizem Ayan
Güllü Sandal Uzun
Mustafa Ekici
Erdinç Ünaldı
Levent Kılıç
Ali Akdoğan
Şule Apras Bilgen
Sedat Kiraz
Ali İhsan Ertenli
Comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological DMARDS
Ulusal Romatoloji Dergisi
rheumatoid arthritis
seropositive
seronegative
b-dmard
title Comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological DMARDS
title_full Comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological DMARDS
title_fullStr Comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological DMARDS
title_full_unstemmed Comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological DMARDS
title_short Comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological DMARDS
title_sort comparison of seropositive and seronegative rheumatoid arthritis patients using or about to be initiated with biological dmards
topic rheumatoid arthritis
seropositive
seronegative
b-dmard
url https://www.raeddergisi.org/articles/comparison-of-seropositive-and-seronegative-rheumatoid-arthritis-patients-using-or-about-to-be-initiated-with-biological-dmards/doi/raed.galenos.2025.22043
work_keys_str_mv AT zehraozsoy comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT serifeasyagerme comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT gizemayan comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT gullusandaluzun comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT mustafaekici comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT erdincunaldı comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT leventkılıc comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT aliakdogan comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT suleaprasbilgen comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT sedatkiraz comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards
AT aliihsanertenli comparisonofseropositiveandseronegativerheumatoidarthritispatientsusingorabouttobeinitiatedwithbiologicaldmards